

Catalog # 10-4827 **IPI-549** 1693758-51-8

(S)-2-Amino-N-[1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3carboxamide

Lot # FBS1094

IPI-549 is a potent and highly selective inhibitor of PI3K- γ in both biochemical (IC₅₀ = 16 nM) and cellular (IC₅₀ = 12.2 nM) assays. 1 Macrophage PI3K-γ has been found to be a critical switch between immune stimulation and suppression. 2 IPI-549 has been used to reshape tumor immune microenvironments and promote cytotoxic T-cell-mediated tumor regression. Resistance to immune checkpoint blockade in 4T1 and B16-GMCSF tumors was overcome when anti-PD-1 or anti-CTLA4 therapies were combined with PI3Kγ inhibition via IPI-549.3 IPI-549 mono-treatment also resulted in tumor growth inhibition in several cancer cell lines.3 IPI-549 has also been shown to modulate P-glycoprotein-mediated multidrug resistance.4

- Evans et al. (2016) Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-q Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate; ACS Med.Chem.Lett. 7 862
- Kaneda et al. (2016) PI3Ky is a molecular switch that controls immune suppression; Nature 539 437
- De Henau et al. (2016); Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells; Nature 539 443
- De Vera et al. (2019); Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo; Cancer Letters 442 91

PHYSICAL DATA

Molecular Weight: 528.56 Molecular Formula: $C_{30}H_{24}N_8O_2$ Purity: >98% by HPLC NMR: (Conforms)

DMSO (>25 mg/ml)

Solubility: Physical Description: Pale yellow solid

Storage and Stability: Store as supplied at -20°C for up to 1 year from the date of purchase. Solutions in

DMSO may be stored at -20°C for up to 1 month.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.